TL;DR
CagriSema combines cagrilintide and semaglutide in an investigational once-weekly injection. The American Diabetes Association reported weight loss of up to 22.7% in studied adults without diabetes and 15.7% in those with type 2 diabetes. These trial results depend on the population and analysis used; they do not predict individual outcomes. As of September 7, 2026, the supplied sources do not establish FDA approval, a US launch date, or a US price.
What is CagriSema?
CagriSema is an investigational combination of cagrilintide and semaglutide, administered in trials as a once-weekly injection.
Source status checked September 7, 2026
- FDA approval established: No
- Confirmed US launch date: None
- Confirmed US price: None
Cagrilintide is an amylin receptor agonist. Semaglutide is a GLP-1 receptor agonist. CagriSema therefore contains a GLP-1 medicine, but it is not another name for semaglutide.
Is CagriSema a GLP-1 drug?
Partly. Semaglutide targets GLP-1 receptors, while cagrilintide acts through the amylin pathway. Calling CagriSema simply “a GLP-1” omits one of its two active ingredients.
How do cagrilintide and semaglutide work together?
The combination is being studied for its effects on appetite, food intake, body weight, and glucose regulation. A proposed mechanism cannot predict an individual result or prove superiority over an approved treatment.
CagriSema weight-loss trial results: what the numbers measure
Trial percentages require context. We look at the patient group, treatment period, dose, comparator, discontinuations, and statistical method before drawing conclusions.
| Study | Population | Reported finding |
|---|---|---|
| REDEFINE 1 | Adults with overweight or obesity without diabetes | Weight loss of up to 22.7% |
| REDEFINE 2 | Adults with excess weight and type 2 diabetes | Weight loss of up to 15.7% |
| REIMAGINE 1 | Adults with type 2 diabetes inadequately controlled by diet and exercise | Studied glucose control and body-weight outcomes |
The ADA figures are study-level findings, not promised results. An analysis that assumes participants remain on treatment may answer a different question from one that accounts for treatment discontinuation and missing observations.
REDEFINE 1 results in adults with obesity or overweight
REDEFINE 1 studied CagriSema in adults without diabetes. The American Diabetes Association reported weight loss of up to 22.7%.
That figure should remain tied to the study population and reported analysis. We recommend checking the full peer-reviewed publication before comparing detailed completion, discontinuation, or treatment-arm results.
REDEFINE 2 results in adults with type 2 diabetes
REDEFINE 2 studied adults with type 2 diabetes and excess body weight. The ADA reported weight loss of up to 15.7%.
Results in people with type 2 diabetes should not be treated as forecasts for people without diabetes. Enrollment criteria, health conditions, background treatment, and treatment response can differ.
The CagriSema Phase 3 trial program
Different CagriSema trials answer different clinical questions.
| Study | Population and focus |
|---|---|
| REDEFINE 1 | Weight management in adults without diabetes |
| REDEFINE 2 | Weight management in adults with type 2 diabetes |
| REIMAGINE 1 | Glucose control in adults with type 2 diabetes inadequately controlled by diet and exercise |
Phase 3 findings do not create an approved indication. Regulatory authorities must review the complete evidence before approving a product and its label.
REDEFINE trials for weight management
REDEFINE trials examine weight-related outcomes in defined populations. Their endpoints, comparators, dose plans, and approaches to missing data may differ, so we do not treat their results as interchangeable.
REIMAGINE trials for type 2 diabetes
REIMAGINE studies focus on type 2 diabetes. REIMAGINE 1 was a randomized, double-blind Phase 3a study conducted at 42 sites in six countries. It compared two CagriSema dose levels with matching placebo over 40 weeks.
CagriSema side effects, dropouts, and safety limits
The supplied excerpts do not provide complete, arm-level rates for adverse events, serious events, withdrawals, or treatment discontinuation. We therefore do not quote unsupported percentages.
Anyone assessing CagriSema research should review the full trial publication for:
- Common adverse events
- Serious adverse events
- Treatment discontinuations
- Dose reductions or interruptions
- Follow-up duration
Did trials find new safety concerns?
Safety conclusions apply only to the populations, doses, and follow-up periods studied. Even when investigators describe findings as consistent with known drug-class profiles, that does not mean every risk is known or that the treatment is suitable for everyone.
Why discontinuation rates matter
Average results can look different when participants stop treatment. Stopping the study medicine also differs from leaving a study entirely, because researchers may continue collecting data after treatment ends.
CagriSema vs semaglutide, Ozempic, and Wegovy
CagriSema contains cagrilintide plus semaglutide. Ozempic and Wegovy contain semaglutide alone and are established products with specific approved labels.
How is CagriSema different from Ozempic?
CagriSema combines two active ingredients and remains investigational in the supplied sources. Ozempic contains semaglutide alone. The products are not interchangeable, and a CagriSema trial result does not change Ozempic’s approved uses.
How is CagriSema different from Wegovy?
Wegovy also contains semaglutide alone, while CagriSema adds cagrilintide. They use different treatment plans and have different regulatory status. A higher percentage from one trial does not prove better results for an individual patient.
CagriSema vs tirzepatide, Mounjaro, and Zepbound
CagriSema combines amylin and GLP-1 receptor activity. Tirzepatide, the active ingredient in Mounjaro and Zepbound, targets GIP and GLP-1 receptors.
The cited sources do not include a direct randomized comparison proving that CagriSema is better than either tirzepatide product.
Why cross-trial weight-loss rankings can mislead
Separate trials may differ in diabetes status, eligibility rules, starting weight, dose escalation, adherence, follow-up, and missing-data methods. Comparing headline percentages cannot replace a direct, randomized trial.
What matters beyond the average percentage
We consider more than average weight change:
- Side effects and serious warnings
- Dose tolerance
- Treatment discontinuation
- Contraindications
- Approved indication
- Long-term maintenance
- Cost, coverage, and supply
CagriSema approval, availability, release date, and price
As of September 7, 2026, the supplied sources do not establish an FDA-approved CagriSema label, confirmed US release date, or official US price.
Trial completion, conference presentations, and registry updates are not regulatory approval. We do not turn projected filing or review dates into promised launch dates.
When will CagriSema be available?
The reviewed material does not confirm when CagriSema will become commercially available in the United States. Clinical-trial access is not the same as routine pharmacy availability.
Does CagriSema have a confirmed price?
No confirmed US price appears in the supplied sources. Trial findings cannot predict list price, insurance coverage, discounts, cash cost, or supply. Even after launch, list price and patient cost may differ.
Can you buy CagriSema online now?
The reviewed sources do not establish a commercially available, FDA-approved CagriSema product. A website or vial using the name cannot verify its ingredients, strength, purity, sterility, storage, or manufacturer.
How to check a CagriSema claim on Reddit or social media
Trace the claim to an original clinical-trial record, peer-reviewed paper, regulatory record, or manufacturer document. Check the population, dose, study length, analysis method, and publication date rather than relying on screenshots.
Why separate ingredient access is not the same product
Combining semaglutide with a substance marketed as cagrilintide does not recreate the studied product. Formulation, dose ratio, manufacturing controls, and storage all matter.
Patients considering compounded medicine can read our guide to checks for a compounded semaglutide vial. It does not validate products sold as CagriSema.
What patients can do while CagriSema remains investigational
We recommend discussing currently available options with a licensed clinician rather than waiting for an unconfirmed launch. A review should cover medical history, current medicines, treatment goals, contraindications, previous side effects, cost, and supply.
Through Temi’s medication platform, patients can complete an online intake, meet with a clinician where available, and manage eligible prescriptions and follow-up care. We do not prescribe investigational CagriSema outside a lawful clinical trial.
What to bring to a weight-loss care visit
Bring a list of prescriptions, supplements, allergies, diagnoses, previous weight-management treatments, recent laboratory results, and relevant insurance information. Patients needing help with an existing prescription can use our prescription refill support.
When to seek urgent medical care
Seek urgent assessment for severe or persistent symptoms, an allergic reaction, intense abdominal pain, repeated vomiting, fainting, or any emergency symptoms identified by a clinician. Less severe side effects should still be discussed during follow-up.
CagriSema questions, answered
Is CagriSema a form of semaglutide?
It contains semaglutide, but also includes cagrilintide. It is not interchangeable with a semaglutide-only product.
Is CagriSema better than Mounjaro or Zepbound?
The reviewed sources contain no direct randomized evidence proving that it is better.
When will CagriSema be available in the United States?
The supplied sources do not establish a confirmed US release date as of September 7, 2026.
What were the main CagriSema trial results?
The ADA reported weight loss of up to 22.7% in studied adults without diabetes and 15.7% in those with type 2 diabetes. These are population-specific findings, not individual forecasts.
FAQ
Is CagriSema FDA approved?
FDA approval is not established in the supplied sources. Patients should verify current status through official regulatory records.
Is CagriSema the same as Ozempic?
No. CagriSema combines cagrilintide and semaglutide; Ozempic contains semaglutide alone.
Is CagriSema better than Mounjaro?
No direct comparison in the reviewed evidence proves that claim. Cross-trial percentages are not enough.
Can I purchase CagriSema online?
The sources do not establish an approved commercial product. We recommend avoiding products whose ingredients, manufacturer, sterility, and regulatory status cannot be verified.
Review approved treatment options now
Use Temi to request a clinician review of approved treatment options, current prescriptions, side effects, refill needs, and costs. Eligibility depends on an individual medical assessment.
